Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,16414866,flow rate,"HPLC was performed on a reversed phase C18 column (flow rate 1.5 ml/min, UV = 230 nm) with 0.02 M buffer of KH2PO4 (Adjusted pH 3.5 with Phosphoric Acid) and Methanol (40: 60) whereas extraction of the drug from the plasma was carried out by deproteinization of plasma according to classical method described in previous studies (Obaid A. et al., 1999).",Bioavailability study of tablet Bezafibrate 200 mg (Lipocor). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16414866/),[ml] / [min],1.5,494,DB01393,Bezafibrate
,16414866,Peak level (Tmax),Peak level (Tmax) of Bezafibrate Tablet 200 mg (Lipocor) was observed at about 1.42 +/- 0.53 hours after the dose and practically free Bezafibrate Tablet 200 mg (Lipocor) could be detected in blood after 9 hours.,Bioavailability study of tablet Bezafibrate 200 mg (Lipocor). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16414866/),h,1.42,495,DB01393,Bezafibrate
,16414866,Cmax,Cmax of the investigated formulation of Lipocor register mark or target was 1732 +/- 374.2 ng/ml.,Bioavailability study of tablet Bezafibrate 200 mg (Lipocor). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16414866/),[ng] / [ml],1732,496,DB01393,Bezafibrate
,16414866,Area under curve (AUC),Area under curve (AUC) was 5198.65 +/- 1231.8 ng.,Bioavailability study of tablet Bezafibrate 200 mg (Lipocor). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16414866/),ng,5198.65,497,DB01393,Bezafibrate
,7319135,areas under the serum concentration curves,The areas under the serum concentration curves were not statistically significantly different (median of 31.3 mg .,Comparative pharmacokinetics of 400 mg bezafibrate after a single oral administration of a new slow-release preparation and the currently available commercial form. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7319135/),mg,31.3,5791,DB01393,Bezafibrate
,8489566,AUEC,"Neglecting the dose difference, the AUEC of A (28.8 micrograms/ml.h) was equal to that of B (27.6 micrograms/ml.h), whereas the bioavailability of A appeared to be higher than that of B when AUEC was corrected for dose (AUEC ratio = 137%).",[Comparison of the pharmacokinetics of a quick-release bezafibrate formulation with a sustained-release formulation. 1. Single-dose administration]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8489566/),[μg] / [h·ml],28.8,27201,DB01393,Bezafibrate
,8489566,AUEC,"Neglecting the dose difference, the AUEC of A (28.8 micrograms/ml.h) was equal to that of B (27.6 micrograms/ml.h), whereas the bioavailability of A appeared to be higher than that of B when AUEC was corrected for dose (AUEC ratio = 137%).",[Comparison of the pharmacokinetics of a quick-release bezafibrate formulation with a sustained-release formulation. 1. Single-dose administration]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8489566/),[μg] / [h·ml],27.6,27202,DB01393,Bezafibrate
,8489566,AUEC ratio,"Neglecting the dose difference, the AUEC of A (28.8 micrograms/ml.h) was equal to that of B (27.6 micrograms/ml.h), whereas the bioavailability of A appeared to be higher than that of B when AUEC was corrected for dose (AUEC ratio = 137%).",[Comparison of the pharmacokinetics of a quick-release bezafibrate formulation with a sustained-release formulation. 1. Single-dose administration]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8489566/),%,137,27203,DB01393,Bezafibrate
,8489567,Cmax,"The means of Cmax (12.5 micrograms/ml) and AUC (66.8 micrograms/ml.h) for preparation A were considerably higher than for B (Cmax: 6.6 micrograms/ml, AUC: 39.8 micrograms/ml.h), whereas no differences were found regarding Tcav (A: 8.9 h, B: 8.3 h) and PTF (A: 4.6, B; 4.1).",[Comparison of the pharmacokinetics of a quick-release bezafibrate formulation with a sustained-release formulation. 2. Multiple-dose administration and chronopharmacokinetics]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8489567/),[μg] / [ml],12.5,70392,DB01393,Bezafibrate
,8489567,AUC,"The means of Cmax (12.5 micrograms/ml) and AUC (66.8 micrograms/ml.h) for preparation A were considerably higher than for B (Cmax: 6.6 micrograms/ml, AUC: 39.8 micrograms/ml.h), whereas no differences were found regarding Tcav (A: 8.9 h, B: 8.3 h) and PTF (A: 4.6, B; 4.1).",[Comparison of the pharmacokinetics of a quick-release bezafibrate formulation with a sustained-release formulation. 2. Multiple-dose administration and chronopharmacokinetics]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8489567/),[μg] / [h·ml],66.8,70393,DB01393,Bezafibrate
,8489567,Cmax,"The means of Cmax (12.5 micrograms/ml) and AUC (66.8 micrograms/ml.h) for preparation A were considerably higher than for B (Cmax: 6.6 micrograms/ml, AUC: 39.8 micrograms/ml.h), whereas no differences were found regarding Tcav (A: 8.9 h, B: 8.3 h) and PTF (A: 4.6, B; 4.1).",[Comparison of the pharmacokinetics of a quick-release bezafibrate formulation with a sustained-release formulation. 2. Multiple-dose administration and chronopharmacokinetics]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8489567/),[μg] / [ml],6.6,70394,DB01393,Bezafibrate
,8489567,AUC,"The means of Cmax (12.5 micrograms/ml) and AUC (66.8 micrograms/ml.h) for preparation A were considerably higher than for B (Cmax: 6.6 micrograms/ml, AUC: 39.8 micrograms/ml.h), whereas no differences were found regarding Tcav (A: 8.9 h, B: 8.3 h) and PTF (A: 4.6, B; 4.1).",[Comparison of the pharmacokinetics of a quick-release bezafibrate formulation with a sustained-release formulation. 2. Multiple-dose administration and chronopharmacokinetics]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8489567/),[μg] / [h·ml],39.8,70395,DB01393,Bezafibrate
,8489567,Tcav,"The means of Cmax (12.5 micrograms/ml) and AUC (66.8 micrograms/ml.h) for preparation A were considerably higher than for B (Cmax: 6.6 micrograms/ml, AUC: 39.8 micrograms/ml.h), whereas no differences were found regarding Tcav (A: 8.9 h, B: 8.3 h) and PTF (A: 4.6, B; 4.1).",[Comparison of the pharmacokinetics of a quick-release bezafibrate formulation with a sustained-release formulation. 2. Multiple-dose administration and chronopharmacokinetics]. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8489567/),h,8.9,70396,DB01393,Bezafibrate
,8489567,Tcav,"The means of Cmax (12.5 micrograms/ml) and AUC (66.8 micrograms/ml.h) for preparation A were considerably higher than for B (Cmax: 6.6 micrograms/ml, AUC: 39.8 micrograms/ml.h), whereas no differences were found regarding Tcav (A: 8.9 h, B: 8.3 h) and PTF (A: 4.6, B; 4.1).",[Comparison of the pharmacokinetics of a quick-release bezafibrate formulation with a sustained-release formulation. 2. Multiple-dose administration and chronopharmacokinetics]. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8489567/),h,8.3,70397,DB01393,Bezafibrate
,8489567,Tcav,"The means of Cmax (12.5 micrograms/ml) and AUC (66.8 micrograms/ml.h) for preparation A were considerably higher than for B (Cmax: 6.6 micrograms/ml, AUC: 39.8 micrograms/ml.h), whereas no differences were found regarding Tcav (A: 8.9 h, B: 8.3 h) and PTF (A: 4.6, B; 4.1).",[Comparison of the pharmacokinetics of a quick-release bezafibrate formulation with a sustained-release formulation. 2. Multiple-dose administration and chronopharmacokinetics]. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8489567/),,4.6,70398,DB01393,Bezafibrate
,8489567,Tcav,"The means of Cmax (12.5 micrograms/ml) and AUC (66.8 micrograms/ml.h) for preparation A were considerably higher than for B (Cmax: 6.6 micrograms/ml, AUC: 39.8 micrograms/ml.h), whereas no differences were found regarding Tcav (A: 8.9 h, B: 8.3 h) and PTF (A: 4.6, B; 4.1).",[Comparison of the pharmacokinetics of a quick-release bezafibrate formulation with a sustained-release formulation. 2. Multiple-dose administration and chronopharmacokinetics]. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8489567/),,4.1,70399,DB01393,Bezafibrate
,8489567,AUC ratio,An AUC ratio for A/B of 119% (CI90%: 108-132%) was determined after dose correction.,[Comparison of the pharmacokinetics of a quick-release bezafibrate formulation with a sustained-release formulation. 2. Multiple-dose administration and chronopharmacokinetics]. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8489567/),%,119,70400,DB01393,Bezafibrate
,8489567,AUC/AUEC ratio,"For A an AUC/AUEC ratio of 110% was found when comparing multiple versus single-dose application, whereas this ratio with 136% appeared to be considerably higher for B.",[Comparison of the pharmacokinetics of a quick-release bezafibrate formulation with a sustained-release formulation. 2. Multiple-dose administration and chronopharmacokinetics]. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8489567/),%,110,70401,DB01393,Bezafibrate
,8489567,tmax,"During night-time the AUC was (insignificantly) 12% higher than during day-time, whereas the apparent elimination halflife time was 40% longer at night (p < 0.025), which corresponded to an extended tmax of median 3 h during night-time as compared to 1.75 h at day-time.",[Comparison of the pharmacokinetics of a quick-release bezafibrate formulation with a sustained-release formulation. 2. Multiple-dose administration and chronopharmacokinetics]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8489567/),h,3,70402,DB01393,Bezafibrate
,8489567,tmax,"During night-time the AUC was (insignificantly) 12% higher than during day-time, whereas the apparent elimination halflife time was 40% longer at night (p < 0.025), which corresponded to an extended tmax of median 3 h during night-time as compared to 1.75 h at day-time.",[Comparison of the pharmacokinetics of a quick-release bezafibrate formulation with a sustained-release formulation. 2. Multiple-dose administration and chronopharmacokinetics]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8489567/),h,1.75,70403,DB01393,Bezafibrate
,19007489,flow rate,"Chromatographic separation was achieved on a C18 column by isocratic elution with acetonitrile-ammonium acetate aqueous solution (10 mmol/L; pH 4.0) (44:56, v/v) at a flow rate of 1.0 mL/min.",HPLC method for the determination of bezafibrate in human plasma and application to a pharmacokinetic study of bezafibrate dispersible tablet. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19007489/),[ml] / [min],1.0,75888,DB01393,Bezafibrate
,19007489,Relative bioavailability,Relative bioavailability was 105.0 +/- 15.7%.,HPLC method for the determination of bezafibrate in human plasma and application to a pharmacokinetic study of bezafibrate dispersible tablet. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19007489/),%,105.0,75889,DB01393,Bezafibrate
,20515529,flow rate,"Bezafibrate was separated on a C(18) analytical column (150 x 4.6 mm i.d., 5 microm particle size) with 0.01 M phosphate buffer (pH 3.5)-acetonitrile-methanol (50:40:10) as mobile phase at a flow rate of 1.0 mL/min.",HPLC determination of bezafibrate in human plasma and its application to pharmacokinetics studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20515529/),[ml] / [min],1.0,112246,DB01393,Bezafibrate
,7318880,plasma half-life,"Eight of the patients had moderately impaired renal function, with a creatinine clearance between 20 and 40 ml/min; the mean plasma half-life of bezafibrate in them was 7.8 +3.9 h (SD) and the plasma clearance was 0.03 +0.02 1/kg .",Clinical pharmacokinetics of bezafibrate in patients with impaired renal function. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7318880/),h,7.8,118239,DB01393,Bezafibrate
,7318880,plasma clearance,"Eight of the patients had moderately impaired renal function, with a creatinine clearance between 20 and 40 ml/min; the mean plasma half-life of bezafibrate in them was 7.8 +3.9 h (SD) and the plasma clearance was 0.03 +0.02 1/kg .",Clinical pharmacokinetics of bezafibrate in patients with impaired renal function. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7318880/),[1] / [kg],0.03,118240,DB01393,Bezafibrate
shorter,7318880,plasma half-life,"Three of the patients had a creatinine clearance greater than 40 ml/min; in them the plasma half-life was shorter, 4.6 +1.2 h, and the plasma clearance was higher, 0.06 +0.01 1/kg .",Clinical pharmacokinetics of bezafibrate in patients with impaired renal function. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7318880/),h,4.6,118241,DB01393,Bezafibrate
higher,7318880,plasma clearance,"Three of the patients had a creatinine clearance greater than 40 ml/min; in them the plasma half-life was shorter, 4.6 +1.2 h, and the plasma clearance was higher, 0.06 +0.01 1/kg .",Clinical pharmacokinetics of bezafibrate in patients with impaired renal function. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7318880/),[1] / [kg],0.06,118242,DB01393,Bezafibrate
,7318880,plasma half-life,"This patient had a plasma half-life of 20.l h, which is ten times longer than has been reported in healthy volunteers.",Clinical pharmacokinetics of bezafibrate in patients with impaired renal function. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7318880/),h,20.l,118243,DB01393,Bezafibrate
,3784441,Elimination half-lives,Elimination half-lives were 17 h at start and 22 h after 12 weeks compared with 2 h in subjects with normal renal function.,Lipid lowering treatment with bezafibrate in patients on chronic haemodialysis: pharmacokinetics and effects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3784441/),h,17,157951,DB01393,Bezafibrate
,3784441,Elimination half-lives,Elimination half-lives were 17 h at start and 22 h after 12 weeks compared with 2 h in subjects with normal renal function.,Lipid lowering treatment with bezafibrate in patients on chronic haemodialysis: pharmacokinetics and effects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3784441/),h,22,157952,DB01393,Bezafibrate
,3784441,Elimination half-lives,Elimination half-lives were 17 h at start and 22 h after 12 weeks compared with 2 h in subjects with normal renal function.,Lipid lowering treatment with bezafibrate in patients on chronic haemodialysis: pharmacokinetics and effects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3784441/),h,2,157953,DB01393,Bezafibrate
,3784441,therapeutic serum concentration,"Dose reduction to 200 mg every 3rd day was necessary and resulted in a mean therapeutic serum concentration of 3.4 mg/l, which was similar to 3.0 mg/l of normal subjects, who received the dose optimal for lowering of lipids (200 mg 3 X/day).",Lipid lowering treatment with bezafibrate in patients on chronic haemodialysis: pharmacokinetics and effects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3784441/),[mg] / [l],3.4,157954,DB01393,Bezafibrate
,3784441,therapeutic serum concentration,"Dose reduction to 200 mg every 3rd day was necessary and resulted in a mean therapeutic serum concentration of 3.4 mg/l, which was similar to 3.0 mg/l of normal subjects, who received the dose optimal for lowering of lipids (200 mg 3 X/day).",Lipid lowering treatment with bezafibrate in patients on chronic haemodialysis: pharmacokinetics and effects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3784441/),[mg] / [l],3.0,157955,DB01393,Bezafibrate
,15373931,half-life,The mean half-life of repaglinide was 1.3 h in all phases.,Lack of effect of bezafibrate and fenofibrate on the pharmacokinetics and pharmacodynamics of repaglinide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15373931/),h,1.3,158397,DB01393,Bezafibrate
,3583496,plasma half-life,"There was an increase of the plasma half-life from 1.9 to 5.5 h, but a possibility of accumulation could be excluded.",Normal and slow-release formulations of bezafibrate: a comparative pharmacokinetic study in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3583496/),h,1.9,177688,DB01393,Bezafibrate
,3583496,plasma half-life,"There was an increase of the plasma half-life from 1.9 to 5.5 h, but a possibility of accumulation could be excluded.",Normal and slow-release formulations of bezafibrate: a comparative pharmacokinetic study in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3583496/),h,5.5,177689,DB01393,Bezafibrate
,21763220,ch,The method had a chromatographic run time of 3.4 min and a linear calibration curve over the range 0.1-60 μg/mL (r>0.99).,Ciprofibrate quantification in human plasma by high-performance liquid chromatography coupled with electrospray tandem mass spectrometry for pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21763220/),min,3.4,204651,DB01393,Bezafibrate
,21763220,run time,The method had a chromatographic run time of 3.4 min and a linear calibration curve over the range 0.1-60 μg/mL (r>0.99).,Ciprofibrate quantification in human plasma by high-performance liquid chromatography coupled with electrospray tandem mass spectrometry for pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21763220/),min,3.4,204652,DB01393,Bezafibrate
,21763220,recovery,"The recovery of ciprofibrate was 81.2%, 73.3% and 76.2% for the 0.3, 5.0 and 48.0 ng/mL standard concentrations, respectively.",Ciprofibrate quantification in human plasma by high-performance liquid chromatography coupled with electrospray tandem mass spectrometry for pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21763220/),%,81.2,204653,DB01393,Bezafibrate
,21763220,recovery,"The recovery of ciprofibrate was 81.2%, 73.3% and 76.2% for the 0.3, 5.0 and 48.0 ng/mL standard concentrations, respectively.",Ciprofibrate quantification in human plasma by high-performance liquid chromatography coupled with electrospray tandem mass spectrometry for pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21763220/),%,73.3,204654,DB01393,Bezafibrate
,21763220,recovery,"The recovery of ciprofibrate was 81.2%, 73.3% and 76.2% for the 0.3, 5.0 and 48.0 ng/mL standard concentrations, respectively.",Ciprofibrate quantification in human plasma by high-performance liquid chromatography coupled with electrospray tandem mass spectrometry for pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21763220/),%,76.2,204655,DB01393,Bezafibrate
,1820889,relative bioavailability,The relative bioavailability based on (C: 1st-Dose-A) ratio of AUC infinity o was within the range 100 +/- 20%.,Comparative pharmacokinetics of two oral bezafibrate preparations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820889/),%,100,222015,DB01393,Bezafibrate
,2815833,t1/2,"2. After oral administration of single daily doses for 7 days, the plasma elimination half-life for bezafibrate was rapid (t1/2 of 4-5 h) in comparison to ciprofibrate (t1/2 of 76 h).",The comparative pharmacokinetics and gastric toxicity of bezafibrate and ciprofibrate in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2815833/),h,4-5,237590,DB01393,Bezafibrate
,2815833,t1/2,"2. After oral administration of single daily doses for 7 days, the plasma elimination half-life for bezafibrate was rapid (t1/2 of 4-5 h) in comparison to ciprofibrate (t1/2 of 76 h).",The comparative pharmacokinetics and gastric toxicity of bezafibrate and ciprofibrate in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2815833/),h,76,237591,DB01393,Bezafibrate
,2815833,area under the plasma drug concentration versus time curve (AUC) 0-24,"3. The area under the plasma drug concentration versus time curve (AUC) 0-24 (micrograms.h/ml +/- SD) for bezafibrate (dose 125 mg/kg per day) was 1553 +/- 334, which was less than half the value of 3748 +/- 358 achieved by ciprofibrate (10 mg/kg per day) after 7 days.",The comparative pharmacokinetics and gastric toxicity of bezafibrate and ciprofibrate in the rat. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2815833/),[h·μg] / [ml],1553,237592,DB01393,Bezafibrate
,2815833,area under the plasma drug concentration versus time curve (AUC) 0-24,"3. The area under the plasma drug concentration versus time curve (AUC) 0-24 (micrograms.h/ml +/- SD) for bezafibrate (dose 125 mg/kg per day) was 1553 +/- 334, which was less than half the value of 3748 +/- 358 achieved by ciprofibrate (10 mg/kg per day) after 7 days.",The comparative pharmacokinetics and gastric toxicity of bezafibrate and ciprofibrate in the rat. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2815833/),[h·μg] / [ml],3748,237593,DB01393,Bezafibrate
,2815833,AUC 0-48,The AUC 0-48 values (micrograms.h/ml +/- SD) achieved were 5124 +/- 450 for bezafibrate compared to 4207 +/- 240 for ciprofibrate.,The comparative pharmacokinetics and gastric toxicity of bezafibrate and ciprofibrate in the rat. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2815833/),[h·μg] / [ml],5124,237594,DB01393,Bezafibrate
,2815833,AUC 0-48,The AUC 0-48 values (micrograms.h/ml +/- SD) achieved were 5124 +/- 450 for bezafibrate compared to 4207 +/- 240 for ciprofibrate.,The comparative pharmacokinetics and gastric toxicity of bezafibrate and ciprofibrate in the rat. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2815833/),[h·μg] / [ml],4207,237595,DB01393,Bezafibrate
,22352317,hepatic clearance,"The in vivo findings were supported by the result from the test phase where hepatic clearance (4.3 mL min⁻¹ kg⁻¹) was decreased by 29% (metabolism inhibition), 43% (transport inhibition) and 57% (metabolism + transport inhibition).",The pharmacokinetics and hepatic disposition of repaglinide in pigs: mechanistic modeling of metabolism and transport. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22352317/),kg⁻¹·min⁻¹·ml,4.3,255723,DB01393,Bezafibrate
